Orchid Pharma Limited Stock Bombay S.E.

Equities

ORCHPHARMA

INE191A01027

Pharmaceuticals

Delayed Bombay S.E. 02:59:27 2024-04-30 EDT 5-day change 1st Jan Change
1,085 INR -0.11% Intraday chart for Orchid Pharma Limited +2.51% +52.07%

Financials

Sales 2024 * 8.45B 101M 139M Sales 2025 * 10.78B 129M 177M Capitalization 55.18B 661M 905M
Net income 2024 * 908M 10.88M 14.9M Net income 2025 * 1.42B 17.03M 23.33M EV / Sales 2024 * 6.41 x
Net cash position 2024 * 1.06B 12.65M 17.32M Net cash position 2025 * 1.2B 14.34M 19.64M EV / Sales 2025 * 5.01 x
P/E ratio 2024 *
60.3 x
P/E ratio 2025 *
38.9 x
Employees 838
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.03%
More Fundamentals * Assessed data
Dynamic Chart
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Orchid Pharma Raises INR4 Billion Via Qualifed Institutional Placement MT
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
CARE Upgrades Rating on Orchid Pharma's Long-term Bank Financing to BBB; Outlook Stable MT
More news
1 day-0.11%
1 week+2.51%
Current month+3.84%
1 month-2.16%
3 months+26.29%
6 months+134.28%
Current year+52.07%
More quotes
1 week
1 041.75
Extreme 1041.75
1 123.05
1 month
1 020.05
Extreme 1020.05
1 219.30
Current year
702.30
Extreme 702.3
1 358.80
1 year
385.05
Extreme 385.05
1 358.80
3 years
260.20
Extreme 260.2
1 659.00
5 years
17.15
Extreme 17.15
2 680.00
10 years
17.15
Extreme 17.15
2 680.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 20-03-30
Director of Finance/CFO - 20-06-28
Compliance Officer - 12-15
Members of the board TitleAgeSince
Chairman 74 20-03-30
Director/Board Member 42 20-03-30
Chief Executive Officer 56 20-03-30
More insiders
Date Price Change Volume
24-04-30 1,085 -0.11% 1 365
24-04-29 1,086 +0.16% 7,930
24-04-26 1,085 -0.75% 7,964
24-04-25 1,093 +2.85% 3,421
24-04-24 1,063 +0.37% 8,112

Delayed Quote Bombay S.E., April 30, 2024 at 02:59 am

More quotes
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,088 INR
Average target price
1,130 INR
Spread / Average Target
+3.86%
Consensus

Annual profits - Rate of surprise